Intracerebral haemorrhage is hard to stop, and must be attacked before, during and after

Affiliations

Comment

David L Tirschwell. BMJ Evid Based Med. 2019 Oct.

. 2019 Oct;24(5):e4.

doi: 10.1136/bmjebm-2018-111083. Epub 2018 Nov 5.

No abstract available

Conflict of interest statement

Competing interests: None declared.

Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial.
Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, Christensen H, Ciccone A, Collins R, Czlonkowska A, Dineen RA, Duley L, Egea-Guerrero JJ, England TJ, Krishnan K, Laska AC, Law ZK, Ozturk S, Pocock SJ, Roberts I, Robinson TG, Roffe C, Seiffge D, Scutt P, Thanabalan J, Werring D, Whynes D, Bath PM; TICH-2 Investigators. Sprigg N, et al. Lancet. 2018 May 26;391(10135):2107-2115. doi: 10.1016/S0140-6736(18)31033-X. Epub 2018 May 16. Lancet. 2018. PMID: 29778325 Free PMC article. Clinical Trial.